Showing 7261-7270 of 9134 results for "".
- FDA Approves Allergan's Aczone Gel, 7.5% for Acne Vulgarishttps://practicaldermatology.com/news/fda-approves-allergans-aczone-gel-75-for-acne-vulgaris/2458681/The FDA approved Allergn’s Aczone (dapsone) Gel, 7.5%, a new prescription topical treatment for acne in patients 12 years of age and older. Aczone Gel, 7.5% delivers proven efficacy to treat both inflammatory and non-inflammatory acne, with a new concentration of dapsone in just once-a-day
- Pioneer in Laser Development to Give Keynote at ASLMS 2016https://practicaldermatology.com/news/pioneer-in-laser-development-to-give-keynote-at-aslms-2016/2458682/Robert Afzal, PhD, a leading expert in high power fiber laser development, will deliver the keynote address at ASLMS 2016, the Annual Conference of the American Society for Laser Medicine & Surgery, Inc. (ASLMS), to be held in Boston, Massachusetts March 30 – April 2, 2016. Dr. Afzal wi
- ChloraDerm Launches Pediatric Offeringhttps://practicaldermatology.com/news/chloraderm-launches-pediatric-offering/2458683/entrotech life sciences (ELS) announced the availability of FDA-Cleared ChloraDerm in a new 1.75"x 1.75" configuration, ideal for pediatric patient use. ChloraDerm is the only transparent film dressing containing the Chlorhexidine Advantage, a safe, colophony-and acid-free, edge-t
- Botox Helps Fuel Allergan's “Better-Than-Expected” Q4 Earningshttps://practicaldermatology.com/news/botox-helps-fuel-allergans-better-than-expected-q4-earnings/2458687/Allergan is reporting “better-than-expected” fourth-quarter earnings, largely fueled by Botox. The company saw a 74 percent increase in Q4 net revenue to $4.2 Billion for Q4 2015, topping the nearly $4.18 billion consensus estimate of S&a
- Tempted by Temptu to Debut at AAD Annual Meetinghttps://practicaldermatology.com/news/tempted-by-temptu-to-debut-at-aad-annual-meeting/2458691/At the upcoming 2016 AAD annual meeting, TEMPTU introduces its groundbreaking TEMPTU Air, the first handheld airbrush makeup device for skin perfection. Using the company’s patented Airpod and Atomized AirFlow™ Technology, TEMPTU Air delivers a micro-fine mist that floa
- Caladrius Biosciences Licenses Dermatology Cell Technology to AiVita Biomedicalhttps://practicaldermatology.com/news/caladrius-biosciences-licenses-dermatology-cell-technology-to-aivita-biomedical/2458698/Caladrius Biosciences, Inc., has licensed exclusive global rights to its cell-derived dermatological technology for topical skin applications to AiVita Biomedical, Inc. The company says this transaction supports its strategy to monetize non-core assets. AiVita, a biotechnology company, wa
- Hidradenitis Suppurativa Ups Risk of Adverse CV Eventshttps://practicaldermatology.com/news/hidradenitis-suppurativa-ups-risk-of-adverse-cv-events/2458696/Hidradenitis suppurativa (HS) may increase risk for adverse cardiovascular outcomes, a new study suggests. HS has been associated with cardiovascular risk factors, such as smoking and obesity, but the risk of cardiovascular disease in patients with HS was unknown. The new study
- FDA Accepts Allergan's sNDA for TEFLARO Use in Childrenhttps://practicaldermatology.com/news/fda-accepts-allergans-snda-for-teflaro-use-in-children/2458700/The U.S. Food and Drug Administration (FDA) has accepted Allergan’s supplemental New Drug Application (sNDA) for IV antibacterial TEFLARO® (ceftaroline fosamil). If approved, this filing will expand the label of TEFLARO beyond adults to include children two months of age a
- Cipher's Sitavig Accepted for Review by Health Canadahttps://practicaldermatology.com/news/ciphers-sitavig-accepted-for-review-by-health-canada/2458701/Cipher Pharmaceuticals Inc.’s New Drug Submission for Sitavig has been accepted for review by Health Canada. Sitavig (acyclovir mucoadhesive buccal tablets) is proposed for the treatment of recurrent herpes labialis in adults. In the United States, Sitavig® is approve
- Traffic-related Air pollution Linked to Facial Lentigeneshttps://practicaldermatology.com/news/traffic-related-air-pollution-linked-to-facial-lentigenes/2458707/High levels of traffic-related air pollution and air pollution-associated gases may increase risk of developing facial lentigenes, new research suggests. "While NO2 exposure is known to be associated with low lung function and lung cancer, the effect o